

Approved



Haiti

Country Operational Plan

FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		396,289		396,289	0	396,289
USAID		39,824,971		39,824,971	6,327,486	46,152,457
HHS/CDC	987,500	46,963,754		47,951,254	0	47,951,254
Total	987,500	87,185,014	0	88,172,514	6,327,486	94,500,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency			On Hold Amount	Total
	State	HHS/CDC	USAID		
CIRC	0	0	0	0	0
HBHC	17,635	3,766,744	2,675,567	0	6,459,946
HKID	70,539	2,691,074	6,662,707	0	9,424,320
HLAB	35,270	2,158,799	1,729,602	0	3,923,671
HMBL	0	0	0	0	0
HMIN	0	0	0	0	0
HTXD	35,270	0	11,374,732	0	11,410,002
HTXS	17,635	16,576,437	6,284,516	0	22,878,588
HVAB	0	0	0	0	0
HVCT	0	3,891,112	3,112,482	0	7,003,594
HVMS	52,905	5,227,629	822,530	0	6,103,064
HVOP	0	525,720	1,547,651	0	2,073,371
HVSI	61,225	3,016,459	495,247	0	3,572,931
HVTB	0	1,725,454	1,237,711	0	2,963,165
IDUP	0	0	0	0	0

Approved



MTCT	17,635	2,818,188	946,432	0	3,782,255
OHSS	35,270	1,328,079	416,527	0	1,779,876
PDCS	17,635	2,273,242	601,059	0	2,891,936
PDTX	35,270	1,952,317	1,918,208	0	3,905,795
	396,289	47,951,254	39,824,971	0	88,172,514



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	5,839,242	0
HKID	9,198,080	0
HVTB	2,805,565	0
PDCS	2,675,616	0
Total Technical Area Planned Funding:	20,518,503	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	3,758,061	0
HVSI	3,388,837	0
OHSS	1,541,617	0
Total Technical Area Planned Funding:	8,688,515	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HVCT	6,838,343	0
HVOP	1,937,885	0
MTCT	3,645,183	0
Total Technical Area Planned Funding:	12,421,411	0

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
-------------	----------------------------	----------------

Approved



HTXD	11,322,408	0
HTXS	22,370,819	0
PDTX	3,625,554	0
Total Technical Area Planned Funding:	37,318,781	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	237,460
	Number of new ANC and L&D clients	246,265
	By: Known positives at entry	2,087
	By: Number of new positives identified	2,711
	Sum of Positives Status disaggregates	4,798
	Required only for DREAMS Countries - By Number of new positives: <15	
	Required only for DREAMS Countries - By Number of new positives: 15-19	
	Required only for DREAMS Countries - By Number of new positives: 20-24	
	Required only for DREAMS Countries - By Number of known positives: <15	
	Required only for DREAMS Countries - By Number of known	



	positives: 15-19	
	Required only for DREAMS Countries - By Number of known positives: 20-24	
	Required only for DREAMS Countries - Denominator: <15	
	Required only for DREAMS Countries - Denominator: <15-19	
	Required only for DREAMS Countries - Denominator: 20-24	
	Required only for DREAMS Countries - Denominator: 25-49	
	Required only for DREAMS Countries - Denominator: 50+	
	Required only for DREAMS Countries - By Number of known positives: 25-49	
	Required only for DREAMS Countries - By Number of known positives: 50+	
	Required only for DREAMS Countries - By Number of new positives: 25-49	
	Required only for DREAMS Countries - By Number of new positives: 50+	
	By Age (DREAMS SNU's ONLY): <15	
	By Age (DREAMS SNU's ONLY): 15-19	
	By Age (DREAMS SNU's ONLY): 20-24	
	By Age (DREAMS SNU's ONLY): 25-49	



	By Age (DREAMS SNU's ONLY): 50+	
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	237,460
	New on ART	2,744
	Already on ART at beginning of current pregnancy	1,812
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0
	Sex: Male	
	Sex: Female	
	Sum of Sex disaggregates	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0
	By Age: 0-60 days	
	By Age: 2 months - 9 years	
	By Age: 10-14	



	By Age: 15-19	
	By Age: 20-24	
	By Age: 25-29	
	By Age: 30-49	
	By Age: 50+	
	Sum of age disaggregates (Prior to FY15)	
	Sum of age disaggregates (FY15-Current)	
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	
	By circumcision technique: Device-based VMMC	
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement		
PrEP_NEW_DSD	PrEP_NEW_DSD Number of	n/a



	individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	
	Number of individuals who have received antiretroviral preexposure	0
	Male 10-14	
	Male 15-19	
	Male 20-24	
	Male 25-49	
	Male 50+	
	Female 10-14	
	Female 15-19	
	Female 20-24	
	Female 25-49	
	Female 50+	
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0
	Total number of people in the target population	0
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	



	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the	n/a



	minimum standards required (DSD)	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	46,522
	Total estimated number of key population in the catchment area	550
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,935
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	16,404
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Transgender who are NOT sex workers (Numerator: Number of	0



	key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	22,183
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the	5,000



	minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	



	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	0
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	985,347
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
Test Result by Age and Sex:		



	Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex:	



	Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	50,173
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	372,866
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	50,173
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	512,135
	Test Result by Aggregated Age and Sex: Negative <15 Male	3,673
	Test Result by Aggregated Age and Sex: Negative 15+ Male	40,414
	Test Result by Aggregated Age and Sex: Negative <15 Female	4,898
	Test Result by Aggregated Age and Sex: Negative 15+ Female	73,478
	Test Result by Aggregated Age and Sex: Positive <15 Male	795
	Test Result by Aggregated Age and Sex: Positive 15+ Male	10,735
	Test Result by Aggregated Age and Sex: Positive <15 Female	795
	Test Result by Aggregated Age and Sex: Positive 15+ Female	14,827
	Test Result by Age: Positive: <1	0
	Test Result by Age: Positive: 1-9	0
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point	



	(Community): Index testing	
	Service Delivery Point	
	(Community): Homebased testing	
	Service Delivery Point	
	(Community): Mobile testing	
	Service Delivery Point	
	(Community): Other	
	Service Delivery Point (Community)	
	by Age: <15 index testing	
	Service Delivery Point (Community)	
	by Age: 15+ index testing	
	Service Delivery Point (Community)	
	by Age: <15 homebased testing	
	Service Delivery Point (Community)	
	by Age: 15+ homebased testing	
	Service Delivery Point (Community)	
	by Age: <15 mobile testing	
	Service Delivery Point (Community)	
	by Age: 15+ mobile testing	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	7,559
	Service Delivery Point (Facility): Outpatient	1,521
	Service Delivery Point (Facility): Pediatric	98,814
	Service Delivery Point (Facility): Malnutrition facilities	0
	Service Delivery Point (Facility): Other PITC	0
	Service Delivery Point (Facility):	626,227



VCT	
Service Delivery Point (Facility): VMMC	0
Service Delivery Point (Facility): PMTCT	237,463
Service Delivery Point (Facility): TB Clinics	13,503
Service Delivery Point (Facility): Index testing	0
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: <15 Other PITC	
Service Delivery Point (Facility) by Age: >15 Other PITC	
Service Delivery Point (Facility) by Age: <15 VCT	
Service Delivery Point (Facility) by Age: >15 VCT	
Service Delivery Point (Facility) by	



	Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	13,500
	Total number of registered new and relapsed TB cases, during the reporting period.	15,098
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24	



	(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	321
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,298
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	476
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,614
	Result: Known HIV positive at service entry	



	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19	



	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
GEND_GBV_DSD	Number of people receiving post-GBV care	1,579
	Age/Sex: <10 Male	
	Age/Sex: 10-14 Male	



	Age/Sex: 15-17 Male	
	Age/Sex: 18-19 Male	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: <10 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	Age/Sex: 18-19 Female	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Sum of Age/Sex Disaggregates	
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	151
	By type of service: Sexual Violence (Post-Rape Care)	1,417
	By PEP service provision (related to sexual violence services provided)	1,374
	Age/Sex: 15-19 Female	
	Age/Sex: 15-19 male	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	78,291
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	0
	Age/Sex: 10-14 Female	



	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	0
	Sum of Age/Sex disaggregates	0
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and	



	sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs	



	Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and	



	sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and	



	sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	37,586
	By Aggregated Age/Sex: 18+ Male	



	By Aggregated Age/Sex: <18 Female	40,705
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,936
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	1,937



	period	
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	



	the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator:	



	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	37
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	788
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	61
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,090
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The	



	number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented	



	HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



TB_ART_TA	<p>TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment</p>	n/a
	<p>The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period</p>	
	<p>The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period</p>	
	<p>Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on</p>	



	ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of	



	registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented	0



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	<p>Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Aggregated Age/Sex: Female <15</p>	



	(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	93,321
	Screened for TB by Age/Sex:<15 Male	1,739
	Screened for TB by Age/Sex: 15+ Male	35,864
	Screened for TB by Age/Sex:<15 Female	2,566
	Screened for TB by Age/Sex: 15+ Female	53,409
	Screen Result: Screened Positive for TB	2,020
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for	2,020



	bacteriologic diagnosis of active TB	
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	2,020
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	297
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	606
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	2,726
	By infants who received their first virologic HIV test between 2 and 12 months of age	1,797
	Sum of Infant Age disaggregates	4,523
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	114
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive	



	virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	77
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	0
	By infants who received their first virologic HIV test between 2 and 12 months of age	0
	Sum of Infant Age disaggregates	0
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	1
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive	



	virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	5
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	93,581
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	2,219
	Aggregated Age/Sex: 15+ Male	36,145
	Aggregated Age/Sex: <15 Female	3,322
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	53,437
	Sum of Aggregated Age/Sex <15	5,541
	Sum of Aggregated Age/Sex 15+	89,582
	Sum of Aggregated Age/Sex disaggregates	95,123
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
Age/Sex: 20-24 Male		



	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	26,335
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	650
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	10,697
	Aggregated Grouping by Age/Sex: <1 Female	
Aggregated Grouping by Age/Sex:	650	



	<15 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	14,671
	Sum of Aggregated Age/Sex disaggregates	26,668
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	70,191
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	93,581
	Numerator: Indication: Routine	63,174
	Numerator: Indication: Targeted	7,017
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	



	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	



	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	84,225
	Denominator: Indication: Targeted	9,356



	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	



	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	



	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	1,293
	Numerator Aggregated Age/Sex: 15+ Male	27,040
	Numerator Aggregated Age/Sex: <15 Female	1,928
	Numerator Aggregated Age/Sex: 15+ Female	39,930
	Denominator Aggregated Age/Sex: <15 Male	1,739
	Denominator Aggregated Age/Sex: 15+ Male	36,024
	Denominator Aggregated Age/Sex: <15 Female	2,569
	Denominator Aggregated Age/Sex: 15+ Female	53,249
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	17,196
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	21,259
	Age/Sex: <1 (Numerator: Number	



	of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on	



	treatment at 12 months after initiating ART	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	



	those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of	



	<p>adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,</p>	



	those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on	348



	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,043
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	515
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,300
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	430
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,547
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated	645



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,837
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	12
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	CD4: Number of laboratories that perform this testing	
	CD4: Number of laboratories that participate in this PT program	
	CD4: Number of laboratories that achieve acceptable successful	



	passing criteria in this PT program	
	Early infant diagnostics: Number of laboratories that perform this testing	
	Early infant diagnostics: Number of laboratories that participate in this PT program	
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	HIV viral load: Number of laboratories that perform this testing	
	HIV viral load: Number of laboratories that participate in this PT program	
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	
	TB diagnostics (Xpert MTB/RIF):	



	Number of laboratories that participate in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	
	Number of HIV Test Kits purchased	945,509
	Number of HIV CD4 Reagents purchased	0
	Number of Condoms purchased	
	Number of HIV Viral Load Reagents purchased	90,862
	Number of HIV ARVs purchased	63,540
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	1,824,871
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	0
HIV Viral Load: Dollars planned	2,829,304	

Approved



	(COP)/ spent (Actual)	
	Condoms: Dollars planned (COP)/ spent (Actual)	1,164,240
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	9,254,749



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
10508	Partners in Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10639	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	25,875,535
12608	Ministre de la Sante Publique et Population, Haiti	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12692	Ministre de la Sante Publique et Population, Haiti	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	15,435,752
12708	Promoteurs Objectif Zéro Sida (Promoteurs de l'Objectif Zéro	NGO	U.S. Department of Health and Human Services/Centers	GHP-State	0



	Sida)		for Disease Control and Prevention		
13569	University of Miami School of Medicine	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13620	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13621	Palladium Group	NGO	U.S. Agency for International Development	GHP-State	693,302
13744	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14564	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	0
14624	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	0



			Prevention		
14627	Catholic Medical Mission Board	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14706	Foundation for Reproductive Health and Family Education	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14710	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14761	Health Through Walls	NGO	U.S. Agency for International Development	GHP-State	710,644
14766	JHPIEGO	University	U.S. Agency for International Development	GHP-State	3,445,167
16722	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	0
16801	Caris Foundation	NGO	U.S. Agency for International Development	GHP-State	3,903,030
16856	University of	University	U.S. Department	GHP-State	2,425,500



	Washington		of Health and Human Services/Centers for Disease Control and Prevention		
17691	Ministre de la Sante Publique et Population, Haiti	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17692	Pathfinder International	NGO	U.S. Agency for International Development	GHP-State	0
18018	FHI 360	NGO	U.S. Agency for International Development	GHP-State	290,043
18047	National Alliance of State and Territorial AIDS Directors	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,270,000
18050	Center for Development and Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,125,000
18086	Measure Evaluation	NGO	U.S. Agency for International Development	GHP-State	0



18266	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,600,000
18267	Partners in Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,800,000
18268	Catholic Medical Mission Board	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,500,000
18269	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,795,000
18270	Foundation for Reproductive Health and Family Education	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,200,000
18425	Right To Care,	NGO	U.S. Agency for	GHP-State	0

Approved



	South Africa		International Development		
18443	JHPIEGO	University	U.S. Agency for International Development	GHP-State	2,878,237



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 10508	Mechanism Name: PIH
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Partners in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 10508			
Mechanism Name: PIH			
Prime Partner Name: Partners in Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10639	Mechanism Name: Global Health Supply Chain Program
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 25,875,535	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 25,875,535	
Funding Source	Funding Amount
GHP-State	25,875,535

Cross-Cutting Budget Attribution(s)

Water	517,511
Condom procurement	1,293,777

Budget Code Information

Mechanism ID:	10639		
Mechanism Name:	Global Health Supply Chain Program		
Prime Partner Name:	Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,880,532	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	592,732	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,698,061	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	347,742	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	216,910	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	2,287,114	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,367,580	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	932,691	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	11,322,408	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,325,895	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,653,870	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
INVS_COMD	Number of HIV Test Kits purchased	945,509
INVS_COMD	Number of HIV CD4 Reagents purchased	0
INVS_COMD	Number of HIV Viral Load Reagents purchased	90,862
INVS_COMD	Number of HIV ARVs purchased	63,540
INVS_COMD	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	1,824,871
INVS_COMD	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	0
INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	2,829,304
INVS_COMD	Condoms: Dollars planned (COP)/ spent (Actual)	1,164,240
INVS_COMD	HIV ARVs: Dollars planned (COP)/ spent (Actual)	9,254,749

Implementing Mechanism Details

Mechanism ID: 12608	Mechanism Name: Blood Safety
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministre de la Sante Publique et Population, Haiti	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 12608			
Mechanism Name: Blood Safety			
Prime Partner Name: Ministre de la Sante Publique et Population, Haiti			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12692	Mechanism Name: MSPP/UGP (National AIDS Strategic Plan)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministre de la Sante Publique et Population, Haiti	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 15,435,752	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 15,435,752	
Funding Source	Funding Amount
GHP-State	15,435,752

Cross-Cutting Budget Attribution(s)

Human Resources for Health	7,350,000
Key Populations: MSM and TG	50,000
Focus Area:	Training of health workers and community outreach



	workers
Focus Area:	Collection and use of strategic information
Key Populations: FSW	50,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Gender: GBV	50,000
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	50,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Motor Vehicles: Purchased	100,000

Budget Code Information

Mechanism ID: 12692			
Mechanism Name: MSPP/UGP (National AIDS Strategic Plan)			
Prime Partner Name: Ministre de la Sante Publique et Population, Haiti			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,376,515	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,293,766	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	548,950	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	735,928	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,860,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,198,188	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	800,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,109,343	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,078,510	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,860,339	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	574,213	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
------------------	-------	------

PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	76,947
PMTCT_ART_DSD	New on ART	813
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	563
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	76,947
PMTCT_STAT_DSD	Number of new ANC and L&D clients	78,819
PMTCT_STAT_DSD	By: Known positives at entry	658
PMTCT_STAT_DSD	By: Number of new positives identified	792
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,450
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0
KP_PREV_DSD	Total estimated number of key population in the catchment area	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0



KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	272,718
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	12,984
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	103,636
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	12,984
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	143,114
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	25,968
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	246,750
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	272,718
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	205
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,726
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15	205

	Female	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,773
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	2,257
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	25,961
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	165,452
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	76,951
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2,097
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,099
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,298
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	37
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	801
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	60
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,201
GEND_GBV_DSD	Number of people receiving post-GBV care	865
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	84
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	781



GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	771
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	11,664
OVC_SERV_DSD	Age/Sex: 18+ Male	0
OVC_SERV_DSD	Age/Sex: 18+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	5,598
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	6,066
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	258
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	258
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	102
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	148
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	22,830

TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	414
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	8,715
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	624
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	13,074
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	493
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	493
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	493
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	74
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	148
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	753
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	612
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,365
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	33
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	26
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	22,830
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	414
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	8,715
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	627
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	13,074
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,041
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	21,789
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	22,830
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,905



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	164
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,762
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	164
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,815
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,905
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	17,123
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	22,830
TX_PVLS_DSD	Numerator: Indication: Routine	15,409
TX_PVLS_DSD	Numerator: Indication: Targeted	1,714
TX_PVLS_DSD	Denominator: Indication: Routine	20,548
TX_PVLS_DSD	Denominator: Indication: Targeted	2,282
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	309
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	6,540
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	469
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	9,805
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	414
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	8,715
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	627
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	13,074
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,255
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,452
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	89



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,485
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	128
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,553
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	110
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,908
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	164
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,270

Implementing Mechanism Details

Mechanism ID: 12708	Mechanism Name: POZ
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Promoteurs Objectif Zéro Sida (Promoteurs de l'Objectif Zéro Sida)	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12708		
Mechanism Name:	POZ		
Prime Partner Name:	Promoteurs Objectif Zéro Sida (Promoteurs de l'Objectif Zéro Sida)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13569	Mechanism Name: University of Miami
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Miami School of Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13569			
Mechanism Name: University of Miami			
Prime Partner Name: University of Miami School of Medicine			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	OHSS	0	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13620	Mechanism Name: GHESKIO 0545
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)



(No data provided.)

Budget Code Information

Mechanism ID:	13620		
Mechanism Name:	GHESKIO 0545		
Prime Partner Name:	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13621	Mechanism Name: Support to UPE
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Palladium Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 693,302	
Applied Pipeline Amount: 512,153	
Total All Funding Sources and Applied Pipeline Amount: 1,205,455	
Funding Source	Funding Amount
GHP-State	693,302

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Leased	180,000
------------------------	---------

Budget Code Information

Mechanism ID: 13621			
Mechanism Name: Support to UPE			
Prime Partner Name: Palladium Group			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	693,302	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13744	Mechanism Name: GHESKIO 541
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13744
Mechanism Name:	GHESKIO 541
Prime Partner Name:	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections



Opportunists			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14564	Mechanism Name: LMG (Leadership, Management and Governance)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 547,055	
Total All Funding Sources and Applied Pipeline Amount: 547,055	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14564		
Mechanism Name:	LMG (Leadership, Management and Governance)		
Prime Partner Name:	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14624	Mechanism Name: University of Maryland
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14624		
Mechanism Name:	University of Maryland		
Prime Partner Name:	University of Maryland		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14627	Mechanism Name: Catholic Medical Mission Board
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Medical Mission Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14627		
Mechanism Name:	Catholic Medical Mission Board		
Prime Partner Name:	Catholic Medical Mission Board		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	15
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	85
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	16
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	93
GEND_GBV_DSD	Number of people receiving post-GBV care	11
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	16
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	17



	TB treatment during the reporting period)	
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	3
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	3
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	3
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	1
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	480
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	121
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	753
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	188
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,233
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	309
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,542
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	11
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	147
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	11
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	183
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	352
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number	0



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	74
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	116

Implementing Mechanism Details

Mechanism ID: 14706	Mechanism Name: FOSREF
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Foundation for Reproductive Health and Family Education	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
-------------------------------------	--



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14706			
Mechanism Name: FOSREF			
Prime Partner Name: Foundation for Reproductive Health and Family Education			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14710	Mechanism Name: ITECH 549
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14710			
Mechanism Name: ITECH 549			
Prime Partner Name: University of Washington			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14761	Mechanism Name: HTW (Health Through Walls)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Through Walls	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 710,644	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 710,644	



Funding Source	Funding Amount
GHP-State	710,644

Cross-Cutting Budget Attribution(s)

Human Resources for Health	21,319
Education	7,106
Water	7,106

Budget Code Information

Mechanism ID:	14761		
Mechanism Name:	HTW (Health Through Walls)		
Prime Partner Name:	Health Through Walls		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	232,027	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	203,742	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	50,492	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	44,585	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	179,798	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0
PMTCT_ART_DSD	New on ART	0
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	0
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0
PMTCT_STAT_DSD	By: Known positives at entry	0
PMTCT_STAT_DSD	By: Number of new positives identified	0
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	0
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0
PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0
PP_PREV_DSD	Total number of people in the target population	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	5,000
KP_PREV_DSD	Total estimated number of key population in the catchment area	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations	5,000



	reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,784
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	71
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,692
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	71
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	950
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	142
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	3,642
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	3,784
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	3
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	39
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	3
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	53
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	142
HTC_TST_DSD	Service Delivery Point (Facility): VCT	3,442
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	200
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	200
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	235
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with	0



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	192
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
GEND_GBV_DSD	Number of people receiving post-GBV care	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	29
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	29
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	28
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	1



	TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	624
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	3
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	454
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	5
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	162
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	14
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	14
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	14
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	2
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	3
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	0
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	0
PMTCT_EID_DSD	Sum of Infant Age disaggregates	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	624
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	3
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	454
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	5
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	162
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	8



TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	616
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	624
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	125
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	92
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	31
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	125
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	470
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	624
TX_PVLS_DSD	Numerator: Indication: Routine	422
TX_PVLS_DSD	Numerator: Indication: Targeted	48
TX_PVLS_DSD	Denominator: Indication: Routine	562
TX_PVLS_DSD	Denominator: Indication: Targeted	62
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	2
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	343
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	4
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	121
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	3
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	454
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	5
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	162
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	64
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	84



	stopped ART, and those lost to follow-up	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	50
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	66
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18

Implementing Mechanism Details

Mechanism ID: 14766	Mechanism Name: SSQH Nord (Services de
----------------------------	---



	Santé de Qualité pour Haïti
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 3,445,167	
Applied Pipeline Amount: 855,694	
Total All Funding Sources and Applied Pipeline Amount: 4,300,861	
Funding Source	Funding Amount
GHP-State	3,445,167

Cross-Cutting Budget Attribution(s)

Gender: GBV	344,069
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Post GBV Care

Budget Code Information

Mechanism ID:	14766		
Mechanism Name:	SSQH Nord (Services de Santé de Qualité pour Haïti)		
Prime Partner Name:	JHPIEGO		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	29,804	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HKID	1,084,281	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	197,548	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	152,438	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	58,981	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	351,177	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,452,212	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	118,726	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	26,777



	their results)	
PMTCT_ART_DSD	New on ART	423
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	184
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	26,777
PMTCT_STAT_DSD	Number of new ANC and L&D clients	27,588
PMTCT_STAT_DSD	By: Known positives at entry	226
PMTCT_STAT_DSD	By: Number of new positives identified	414
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	640
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0
PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0
PP_PREV_DSD	Total number of people in the target population	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0
KP_PREV_DSD	Total estimated number of key population in the catchment area	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	91,855
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,915
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION	35,294



	ONLY: 15+ Male	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,915
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	48,731
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	7,830
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	84,025
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	91,855
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	60
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,052
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	60
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,456
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	0
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	582
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	7,833
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	55,750
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	26,776
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	914
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	914
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	934
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of	17



	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	353
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	22
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	522
GEND_GBV_DSD	Number of people receiving post-GBV care	107
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	10
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	97
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	97
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	14,552
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	6,987
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	7,565
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	109
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	109
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with	47

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	60
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	6,987
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	116
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	2,680
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	172
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	4,019
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	150
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	150
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	150
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	22
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	45
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	397
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	206
PMTCT_EID_DSD	Sum of Infant Age disaggregates	603
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	9
PMTCT_EID_DSD	Number of infants with a positive virological test result	5



	within 12 months of birth	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,987
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	116
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,680
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	172
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,019
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	288
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	6,699
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	6,987
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,478
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	48
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,001
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	48
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,381
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,478
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	5,240
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	6,987
TX_PVLS_DSD	Numerator: Indication: Routine	4,716
TX_PVLS_DSD	Numerator: Indication: Targeted	524
TX_PVLS_DSD	Denominator: Indication: Routine	6,286
TX_PVLS_DSD	Denominator: Indication: Targeted	701
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	87
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	2,011
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	128
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	3,014
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	116



TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	2,680
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	172
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	4,019
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,371
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,866
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	47
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	830
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	72
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,422
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	58
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,002
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	87



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,719

Implementing Mechanism Details

Mechanism ID: 16722	Mechanism Name: HFG (Health Financing and Governance)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 466,010	
Total All Funding Sources and Applied Pipeline Amount: 466,010	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16722		
Mechanism Name:	HFG (Health Financing and Governance)		
Prime Partner Name:	Abt Associates		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	0	0
------------------------	------	---	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	134
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	64
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	70

Implementing Mechanism Details

Mechanism ID: 16801	Mechanism Name: BEST (Byen en ak Sante Timoun)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Caris Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 3,903,030	
Applied Pipeline Amount: 264,634	
Total All Funding Sources and Applied Pipeline Amount: 4,167,664	
Funding Source	Funding Amount
GHP-State	3,903,030

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	3,092
Economic Strengthening	541,796



Education	541,796
-----------	---------

Budget Code Information

Mechanism ID: 16801			
Mechanism Name: BEST (Byen en ak Sante Timoun)			
Prime Partner Name: Caris Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	3,903,030	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
KP_PREV_DSD	Total estimated number of key population in the catchment area	550
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	29,578
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	14,205
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	15,373
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	0
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	0



PMTCT_EID_TA	Sum of Infant Age disaggregates	0
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	1
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	5

Implementing Mechanism Details

Mechanism ID: 16856	Mechanism Name: ITECH 1331
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,425,500	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,425,500	
Funding Source	Funding Amount
GHP-State	2,425,500

Cross-Cutting Budget Attribution(s)

Human Resources for Health	150,000
Education	200,000
Key Populations: MSM and TG	20,000
Focus Area:	Training of health workers and community outreach workers
Key Populations: FSW	30,000
Gender: GBV	20,000
Focus Area:	Post GBV Care
Sub Area:	Capacity building



Budget Code Information

Mechanism ID: 16856			
Mechanism Name: ITECH 1331			
Prime Partner Name: University of Washington			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	100,593	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	63,804	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	224,879	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	706,874	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	187,791	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	128,445	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	91,630	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	864,923	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	56,561	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17691	Mechanism Name: MSPP Research
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministre de la Sante Publique et Population, Haiti	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17691			
Mechanism Name: MSPP Research			
Prime Partner Name: Ministre de la Sante Publique et Population, Haiti			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17692	Mechanism Name: SSQH Centre/Sud (Services de Santé de Qualité pour Haïti)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Pathfinder International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17692		
Mechanism Name:	SSQH Centre/Sud (Services de Santé de Qualité pour Haïti)		
Prime Partner Name:	Pathfinder International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	42,949
PMTCT_ART_DSD	New on ART	425
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	305
PMTCT_STAT_DSD	Number of pregnant women with known HIV status	42,949



	(includes women who were tested for HIV and received their results)	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	44,433
PMTCT_STAT_DSD	By: Known positives at entry	344
PMTCT_STAT_DSD	By: Number of new positives identified	426
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	770
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	83,720
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,303
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	32,388
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,303
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	44,726
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	6,606
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	77,114
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	83,720
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	49
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	712
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	49
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	973
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	293
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	6,604
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0



HTC_TST_DSD	Service Delivery Point (Facility): VCT	32,719
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	42,949
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,156
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,154
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,382
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	23
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	441
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	34
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	656
GEND_GBV_DSD	Number of people receiving post-GBV care	15
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	14
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	9,192
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	4,411
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	4,781
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART	153

	during TB treatment during the reporting period	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	153
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	61
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	86
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	5,309
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	109
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	2,015
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	160
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	3,025
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	115
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	115
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	115
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	14



TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	36
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	433
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	293
PMTCT_EID_DSD	Sum of Infant Age disaggregates	726
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	24
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	17
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	5,309
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	109
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,015
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	160
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	3,025
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	269
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,040
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	5,309
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,211
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	40
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	475
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	40
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	656
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,211
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	3,981
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record	5,309



	and /or laboratory records in the past 12 months.	
TX_PVLS_DSD	Numerator: Indication: Routine	3,584
TX_PVLS_DSD	Numerator: Indication: Targeted	397
TX_PVLS_DSD	Denominator: Indication: Routine	4,776
TX_PVLS_DSD	Denominator: Indication: Targeted	533
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	81
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	1,511
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	123
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	2,266
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	109
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	2,015
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	160
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	3,025
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,324
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,618
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	462
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	38
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	795
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	32



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	567
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	49
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	970

Implementing Mechanism Details

Mechanism ID: 18018	Mechanism Name: Linkages
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 290,043	
Applied Pipeline Amount: 1,441,573	
Total All Funding Sources and Applied Pipeline Amount: 1,731,616	
Funding Source	Funding Amount
GHP-State	290,043

Cross-Cutting Budget Attribution(s)



Key Populations: MSM and TG	250,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	40,043
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs

Budget Code Information

Mechanism ID:	18018		
Mechanism Name:	Linkages		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	112,330	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	99,414	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	78,299	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	71
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	71
PMTCT_STAT_DSD	Number of new ANC and L&D clients	72
PMTCT_STAT_DSD	By: Known positives at entry	2
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	2
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	29,585
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,935
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9,067
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	17,583
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,819



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	142
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,328
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	142
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,207
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	284
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	5,535
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	5,819
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	7
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	94
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	7
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	117
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	283
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	5,208
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	71
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	0
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	571
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	4



TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	216
TB_SCREENDX_DSD	Screened for TB by Age/Sex: <15 Female	6
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	605
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	19
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	19
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	19
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	3
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	831
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	4
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	376
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	6
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	445
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	10
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	821
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	831
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	221
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	94
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	126
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	222
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml)	625



	documented in the medical records and /or supporting laboratory results within the past 12 months.	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	831
TX_PVLS_DSD	Numerator: Indication: Routine	563
TX_PVLS_DSD	Numerator: Indication: Targeted	62
TX_PVLS_DSD	Denominator: Indication: Routine	748
TX_PVLS_DSD	Denominator: Indication: Targeted	83
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	3
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	284
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	4
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	334
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	4
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	376
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	6
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	445
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	13
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	17
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10

Implementing Mechanism Details

Mechanism ID: 18047	Mechanism Name: NASTAD 1525
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Alliance of State and Territorial AIDS Directors	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,270,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,270,000	
Funding Source	Funding Amount
GHP-State	1,270,000

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	80,000
Human Resources for Health	250,000

Budget Code Information



Mechanism ID: 18047			
Mechanism Name: NASTAD 1525			
Prime Partner Name: National Alliance of State and Territorial AIDS Directors			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	642,171	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	93,897	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	96,333	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	91,630	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	345,969	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18050	Mechanism Name: CDS 1528
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Development and Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,125,000	
---	--



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,125,000	
Funding Source	Funding Amount
GHP-State	1,125,000

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	55,000
Human Resources for Health	500,000
Gender: GBV	25,000
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	35,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation

Budget Code Information

Mechanism ID:	18050		
Mechanism Name:	CDS 1528		
Prime Partner Name:	Center for Development and Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	100,593	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	77,807	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	89,951	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	33,528	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	128,445	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	137,444	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	514,811	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	42,421	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,402
PMTCT_ART_DSD	New on ART	92
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	33
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,402
PMTCT_STAT_DSD	Number of new ANC and L&D clients	6,715
PMTCT_STAT_DSD	By: Known positives at entry	40
PMTCT_STAT_DSD	By: Number of new positives identified	90
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	130



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	18,055
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	749
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,953
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	749
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	9,604
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,498
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	16,557
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	18,055
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	13
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	107
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	13
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	152
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	1,496
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	9,962
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	6,402
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	195
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	195

TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	327
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	72
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	113
GEND_GBV_DSD	Number of people receiving post-GBV care	9
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	9
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	40
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	40
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	18
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	0

	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	22
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,271
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	24
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	484
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	34
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	729
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	28
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	28
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	28
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	5
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	8
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	78
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	47
PMTCT_EID_DSD	Sum of Infant Age disaggregates	125

PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	4
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	3
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,271
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	24
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	484
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	34
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	729
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	58
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,213
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,271
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	357
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	9
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	143
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	9
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	196
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	357
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	952
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,271
TX_PVLS_DSD	Numerator: Indication: Routine	858
TX_PVLS_DSD	Numerator: Indication: Targeted	94
TX_PVLS_DSD	Denominator: Indication: Routine	1,144
TX_PVLS_DSD	Denominator: Indication: Targeted	127
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	17
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	364



TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	25
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	546
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	24
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	484
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	34
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	729
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	329
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	432
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	116
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	197
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	151



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	259

Implementing Mechanism Details

Mechanism ID: 18086	Mechanism Name: MEASURE Evaluation Phase IV
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Measure Evaluation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 89,302	
Total All Funding Sources and Applied Pipeline Amount: 89,302	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18086



Mechanism Name:	MEASURE Evaluation Phase IV		
Prime Partner Name:	Measure Evaluation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18266	Mechanism Name: GHESKIO 1924
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 2,600,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,600,000	
Funding Source	Funding Amount
GHP-State	2,600,000

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	60,000
Gender: GBV	150,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation



Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Human Resources for Health	1,800,000
Key Populations: FSW	35,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG	30,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information

Budget Code Information

Mechanism ID:	18266		
Mechanism Name:	GHESKIO 1924		
Prime Partner Name:	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	221,030	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	72,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	190,232	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	105,250	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	90,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	163,514	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	108,120	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,310,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	239,854	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,611
PMTCT_ART_DSD	New on ART	44
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	33
PMTCT_STAT_DSD	Number of pregnant women with known HIV status	4,611



	(includes women who were tested for HIV and received their results)	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	4,652
PMTCT_STAT_DSD	By: Known positives at entry	38
PMTCT_STAT_DSD	By: Number of new positives identified	43
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	81
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	86,729
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,210
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	33,730
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,210
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	46,579
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	6,420
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	80,309
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	86,729
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	86
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	779
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	86
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,076
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	867
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	6,420
HTC_TST_DSD	Service Delivery Point (Facility): VCT	73,004
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	4,611
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,827

TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,827
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,158
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	19
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	712
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	30
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,066
GEND_GBV_DSD	Number of people receiving post-GBV care	320
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	31
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	289
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	289
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	282
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	282
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3

TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	111
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	164
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	13,345
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	141
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	5,196
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	212
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	7,796
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	287
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	287
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	287
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	43
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	86
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	43
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	34
PMTCT_EID_DSD	Sum of Infant Age disaggregates	77
PMTCT_EID_DSD	Number of infants with a positive virological test result	4



	within 2 months of birth	
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	2
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	13,345
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	141
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	5,196
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	212
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	7,796
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	353
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	12,992
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	13,345
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,404
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	38
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	976
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	38
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,352
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,404
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	10,009
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	13,345
TX_PVLS_DSD	Numerator: Indication: Routine	9,008
TX_PVLS_DSD	Numerator: Indication: Targeted	1,001
TX_PVLS_DSD	Denominator: Indication: Routine	12,010
TX_PVLS_DSD	Denominator: Indication: Targeted	1,335
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	106
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	3,897
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	159



TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	5,847
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	141
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	5,196
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	212
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	7,796
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,058
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,390
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	41
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	720
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	62
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,235
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	48
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	837
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the	71



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,434

Implementing Mechanism Details

Mechanism ID: 18267	Mechanism Name: PIH 1926
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Partners in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 6,800,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 6,800,000	
Funding Source	Funding Amount
GHP-State	6,800,000

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	100,000
Food and Nutrition: Commodities	250,000
Human Resources for Health	3,100,000
Gender: GBV	130,000
Focus Area:	Post GBV Care
Sub Area:	Implementation
Key Populations: FSW	45,000
Focus Area:	Training of health workers and community outreach workers



Focus Area:	Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG	45,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information

Budget Code Information

Mechanism ID: 18267			
Mechanism Name: PIH 1926			
Prime Partner Name: Partners in Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	738,868	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,326,188	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	401,838	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	365,977	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	106,243	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	103,019	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	546,202	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	508,465	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,355,236	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	247,964	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	32,082
PMTCT_ART_DSD	New on ART	428
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	294
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	32,082
PMTCT_STAT_DSD	Number of new ANC and L&D clients	34,414
PMTCT_STAT_DSD	By: Known positives at entry	300
PMTCT_STAT_DSD	By: Number of new positives identified	460
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	760
KP_PREV_DSD	Number of key populations reached with individual	0



	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	
KP_PREV_DSD	Total estimated number of key population in the catchment area	0
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0



KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	133,740
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,297
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	52,559
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,297
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	72,587
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	8,594
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	125,146
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	133,740
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15	107



	Male	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,462
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	107
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,022
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	1,185
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	8,592
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	89,929
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	32,082
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,952
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,952
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,981
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	34
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	744
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	51
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,123
GEND_GBV_DSD	Number of people receiving post-GBV care	73



GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	7
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	66
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	66
OVC_SERVDSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	13,171
OVC_SERVDSD	Age/Sex: 18+ Male	0
OVC_SERVDSD	Age/Sex: 18+ Female	0
OVC_SERVDSD	Sum of Age/Sex disaggregates	0
OVC_SERVDSD	By Aggregated Age/Sex: <18 Male	6,321
OVC_SERVDSD	By Aggregated Age/Sex: <18 Female	6,850
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	160
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	161
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	66
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	91



	TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	13,281
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	233
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	5,079
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	350
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	7,619
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	285
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	285
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	285
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	44
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	86
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	520
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	200
PMTCT_EID_DSD	Sum of Infant Age disaggregates	720
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	16
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	6
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	13,281
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	233
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	5,079
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	350
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	7,619
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	583



TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	12,698
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	13,281
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,831
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	88
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,524
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	88
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,111
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,811
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	9,962
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	13,281
TX_PVLS_DSD	Numerator: Indication: Routine	8,963
TX_PVLS_DSD	Numerator: Indication: Targeted	999
TX_PVLS_DSD	Denominator: Indication: Routine	11,952
TX_PVLS_DSD	Denominator: Indication: Targeted	1,329
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	172
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	3,813
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	262
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	5,715
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	233
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	5,079
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	350
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	7,619
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,065
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	3,600



	stopped ART, and those lost to follow-up	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	61
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,071
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	94
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,839
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	72
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,259
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	109
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,160

Implementing Mechanism Details

Mechanism ID: 18268	Mechanism Name: CMMB 1970
----------------------------	----------------------------------



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Medical Mission Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 5,500,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,500,000	
Funding Source	Funding Amount
GHP-State	5,500,000

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	35,000
Food and Nutrition: Commodities	20,000
Human Resources for Health	3,300,000

Budget Code Information

Mechanism ID: 18268			
Mechanism Name: CMMB 1970			
Prime Partner Name: Catholic Medical Mission Board			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	536,496	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	273,377	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	359,806	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	55,879	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	706,446	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	366,518	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,840,390	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	311,088	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	25,796
PMTCT_ART_DSD	New on ART	308
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	206
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	25,796



PMTCT_STAT_DSD	Number of new ANC and L&D clients	27,271
PMTCT_STAT_DSD	By: Known positives at entry	251
PMTCT_STAT_DSD	By: Number of new positives identified	289
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	540
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	129,797
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	13,014
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	43,582
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	13,014
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	60,187
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	26,028
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	103,769
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	129,797
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	125
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,124
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	125
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,556
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	964
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	26,030
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	74,458
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0



HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	25,796
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2,551
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,551
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,700
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	122
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	898
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	184
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,347
GEND_GBV_DSD	Number of people receiving post-GBV care	46
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	5
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	41
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	41
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	487
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	487
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	19

	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	176
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	30
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	262
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	10,689
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	373
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	3,901
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	557
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	5,858
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	229
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	229
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	229
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	34
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	71
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	276
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	227
PMTCT_EID_DSD	Sum of Infant Age disaggregates	503



PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	10
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	8
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	10,689
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	373
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,901
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	557
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,858
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	930
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	9,759
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	10,689
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,860
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	143
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,079
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	143
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,495
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,860
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	8,019
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	10,689
TX_PVLS_DSD	Numerator: Indication: Routine	7,217
TX_PVLS_DSD	Numerator: Indication: Targeted	802
TX_PVLS_DSD	Denominator: Indication: Routine	9,623
TX_PVLS_DSD	Denominator: Indication: Targeted	1,066
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	278
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	2,931



TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	419
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	4,391
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	373
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	3,901
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	557
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	5,858
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,383
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,807
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	482
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	41
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	831
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	37
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	630



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	54
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,086
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	12

Implementing Mechanism Details

Mechanism ID: 18269	Mechanism Name: GHESKIO 1969
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 4,795,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,795,000	
Funding Source	Funding Amount
GHP-State	4,795,000

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	60,000
Human Resources for Health	3,000,000
Gender: GBV	100,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	30,000
Focus Area:	Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG	25,000
Focus Area:	Collection and use of strategic information

Budget Code Information

Mechanism ID:	18269		
Mechanism Name:	GHESKIO 1969		
Prime Partner Name:	Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	418,841	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	136,162	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	153,967	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	55,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	734,462	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,712,850	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	283,718	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	20,702
PMTCT_ART_DSD	New on ART	200
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	185
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	20,702
PMTCT_STAT_DSD	Number of new ANC and L&D clients	21,168
PMTCT_STAT_DSD	By: Known positives at entry	220
PMTCT_STAT_DSD	By: Number of new positives identified	186
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	406
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	151,286
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8,285
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	56,579
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION	8,285



	ONLY: <15 Female	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	78,137
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	16,570
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	134,716
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	151,286
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative <15 Male	3,673
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative 15+ Male	40,414
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative <15 Female	4,898
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative 15+ Female	73,478
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	133
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,561
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	133
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,540
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	1,411
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	1,521
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	15,046
HTC_TST_DSD	Service Delivery Point (Facility): VCT	110,066
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	20,702
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2,540
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,537
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,001
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of	48



	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	968
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	72
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,449
GEND_GBV_DSD	Number of people receiving post-GBV care	132
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	13
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	119
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	86
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0
OVC_SERV_DSD	Age/Sex: 18+ Male	0
OVC_SERV_DSD	Age/Sex: 18+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	408
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	408
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	6

	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	158
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	234
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	17,310
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	295
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	6,629
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	440
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	9,946
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	373
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	373
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	373
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	56
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	112
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	215
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	169
PMTCT_EID_DSD	Sum of Infant Age disaggregates	384



PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	13
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	9
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	17,310
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	295
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	6,629
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	440
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	9,946
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	735
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	16,575
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	17,310
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,704
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	103
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,308
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	103
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,190
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	5,704
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	12,981
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	17,310
TX_PVLS_DSD	Numerator: Indication: Routine	11,688
TX_PVLS_DSD	Numerator: Indication: Targeted	1,293
TX_PVLS_DSD	Denominator: Indication: Routine	15,581
TX_PVLS_DSD	Denominator: Indication: Targeted	1,729
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	218
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	4,974



TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	330
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	7,459
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	295
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	6,629
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	440
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	9,946
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,213
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,848
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	44
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	775
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	66
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,328
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	57
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	997



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	86
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,708

Implementing Mechanism Details

Mechanism ID: 18270	Mechanism Name: FOSREF 1925
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Foundation for Reproductive Health and Family Education	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 1,200,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,200,000	
Funding Source	Funding Amount
GHP-State	1,200,000

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	37,500
Human Resources for Health	800,000
Gender: GBV	25,000
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Key Populations: FSW	50,000
Focus Area:	Implementation of core HIV prevention interventions



	for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Key Populations: MSM and TG	50,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance

Budget Code Information

Mechanism ID: 18270			
Mechanism Name: FOSREF 1925			
Prime Partner Name: Foundation for Reproductive Health and Family Education			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	63,539	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	22,766	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	20,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	160,556	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	525,720	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	MTCT	30,175	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	377,244	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,123
PMTCT_ART_DSD	New on ART	11
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	8
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,123
PMTCT_STAT_DSD	Number of new ANC and L&D clients	1,133
PMTCT_STAT_DSD	By: Known positives at entry	8
PMTCT_STAT_DSD	By: Number of new positives identified	11
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	19
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	11,937
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	7,337
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	4,600



	the minimum standards required)	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,844
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	203
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,125
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	203
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,313
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	406
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	7,438
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	7,844
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	7
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	79
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	7
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	109
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	407
HTC_TST_DSD	Service Delivery Point (Facility): VCT	6,237
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	1,123
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	71
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	71
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	82



TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	32
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	36
GEND_GBV_DSD	Number of people receiving post-GBV care	1
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	10
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	10
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5

TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,104
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	27
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	495
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	6
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	576
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	24
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	24
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	24
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	2
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	7
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	11
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	8
PMTCT_EID_DSD	Sum of Infant Age disaggregates	19
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	1
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	1
TX_CURR_DSD	Number of adults and children receiving antiretroviral	1,104



	therapy (ART)	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	27
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	495
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	6
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	576
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	33
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,071
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,104
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	239
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	4
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	96
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	4
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	135
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	239
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	829
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,104
TX_PVLS_DSD	Numerator: Indication: Routine	746
TX_PVLS_DSD	Numerator: Indication: Targeted	83
TX_PVLS_DSD	Denominator: Indication: Routine	995
TX_PVLS_DSD	Denominator: Indication: Targeted	109
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	20
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	372
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	5
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	432
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	27
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	495
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	6



TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	576
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	121
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	145
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	43
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	72
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	50
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total	87



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
--	--	--

Implementing Mechanism Details

Mechanism ID: 18425	Mechanism Name: EQUIP
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Right To Care, South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 400,000	
Total All Funding Sources and Applied Pipeline Amount: 400,000	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18425		
Mechanism Name:	EQUIP		
Prime Partner Name:	Right To Care, South Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	0	0
-----------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18443	Mechanism Name: SSQH Centre/Sud (Services de Santé de Qualité pour Haïti)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 2,878,237	
Applied Pipeline Amount: 655,597	
Total All Funding Sources and Applied Pipeline Amount: 3,533,834	
Funding Source	Funding Amount
GHP-State	2,878,237

Cross-Cutting Budget Attribution(s)

Condom programming	70,677
Food and Nutrition: Policy, Tools, and Service Delivery	353,383
Gender: GBV	282,707
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	176,692
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Human Resources for Health	459,398



Key Populations: FSW	35,338
Focus Area:	Training of health workers and community outreach workers
Key Populations: MSM and TG	70,677
Focus Area:	Collection and use of strategic information
Water	353,383

Budget Code Information

Mechanism ID: 18443			
Mechanism Name: SSQH Centre/Sud (Services de Santé de Qualité pour Haïti)			
Prime Partner Name: JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	28,074	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	897,513	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	214,839	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	152,438	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	58,981	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	276,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	1,152,853	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	97,139	0

Implementing Mechanism Indicator Information

(No data provided.)

Agency Information - Costs of Doing Business U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		94,040		127,714	94,040	221,754
ICASS		100,466		793,304	100,466	893,770
Indirect Costs		36,250		36,490	36,250	72,740
Management Meetings/Professional Development		27,950		28,495	27,950	56,445
Non-ICASS Administrative Costs		78,360		109,465	78,360	187,825
Staff Program Travel		164,474		0	164,474	164,474
USG Staff Salaries and		1,266,013		0	1,266,013	1,266,013



Benefits - Internationally Recruited						
USG Staff Salaries and Benefits - Locally Recruited		261,460		0	261,460	261,460
Total	0	2,029,013	0	1,095,468	2,029,013	3,124,481

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		725,000		0	725,000	725,000
Computers/IT Services		250,000		0	250,000	250,000
ICASS		920,000		0	920,000	920,000
Institutional Contractors	0	150,000		0	150,000	150,000
Non-ICASS Administrative Costs		1,215,040		0	1,215,040	1,215,040
Staff Program Travel		425,002		0	425,002	425,002
USG Staff	987,500	52,500		0	1,040,000	1,040,000



Salaries and Benefits - Internationally Recruited						
USG Staff Salaries and Benefits - Locally Recruited		2,074,960		0	2,074,960	2,074,960
Total	987,500	5,812,502	0	0	6,800,002	6,800,002

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Staff Program Travel		87,183		0	87,183	87,183
USG Staff Salaries and Benefits - Internationally Recruited		309,106		0	309,106	309,106
USG Staff Salaries and Benefits - Locally Recruited		0		0	0	0
Total	0	396,289	0	0	396,289	396,289

Approved

